Analysts fell to the sidelines weighing in on Aspen Group (ASPU – Research Report) and PharmaCyte Biotech (PMCB – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Aspen Group (ASPU) In a report released yesterday, Darren Aftahi from Roth Capital maintained a Hold rating on Aspen Group, with a price target of $4.00. The company's shares closed last Tuesday at $2.61, close to its 52-week low of $2.60. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-consumer-goods-companies-aspen-group-aspu-and-pharmacyte-biotech-pmcb?utm_source=advfn.com&utm_medium=referral
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more PharmaCyte Biotech Charts.
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more PharmaCyte Biotech Charts.